Raw Material Local Anesthetic Series Lidocaine For Pain Killer 137-58-6

Raw Material Local Anesthetic Series Lidocaine For Pain Killer 137-58-6

Abstract

CAS:137-58-6
MF:C14H22N2O
MW:234.34
EINECS:205-302-8
Melting point:66-69°C
Boiling point:bp4 180-182°; bp2 159-160°
Flash point:9℃
storage temp. Store at RT
solubility ethanol: 4 mg/mL
form powder
color White to slightly yellow
Water Solubility practically insoluble
Merck 14,5482
Stability:Stable. Incompatible with strong oxidizing agents.

Description

Lidocaine, also known as xylocaine and lignocaine, is a medication used to numb tissue in a specific area and to treat ventricular tachycardia.It can also be used for nerve blocks. Lidocaine mixed with a small amount of epinephrine is available to allow larger doses to be used as numbing and to make it last longer.When used as an injectable, it typically begins working within four minutes and lasts for half an hour to three hours.Lidocaine may also be applied directly to the skin for numbing.

Application 

The efficacy profile of lidocaine as a local anesthetic is characterized by a rapid onset of action and intermediate duration of efficacy. Therefore, lidocaine is suitable for infiltration, block, and surface anesthesia. Longer-acting substances such as bupivacaine are sometimes given preference for subdural and epidural anesthesias; lidocaine, though, has the advantage of a rapid onset of action. Epinephrine (adrenaline) vasoconstricts arteries, reducing bleeding and also delays the resorption of lidocaine, almost doubling the duration of anaesthesia. For surface anesthesia, several available formulations can be used for endoscopies, before intubations, etc. Buffering the pH of lidocaine makes local numbing less painful. Lidocaine drops can be used on the eyes for short ophthalmic procedures.There is tentative evidence for topical lidocaine for neuropathic pain.

Lidocaine is also the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment ofventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated. Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine preventative dose is no longer recommended after a myocardial infarction as the overall benefit is not convincing.

COA